The FDA has issued a complete response to an NDA for Crinone (progesterone vaginal gel 8%), from Watson, for use...
Treatment of infertility due to inadequate luteal phase. For use during in-vitro fertilisation, where infertility is mainly due to tubal, idiopathic or endometriosis linked sterility associated with normal ovulatory cycles.
Watson Pharma has received a complete response letter from the FDA for its New Drug Application for Prochieve ( progesterone...
New results show that a change in the formulation of Viread (tenofovir gel), from Gilead Sciences, developed for vaginal use...
The goal of this randomized controlled trial is to test the efficacy of StrataMGT in the management of Genitourinary Syndrome of Menopause (GSM) compared to estrogen therapy.
Lutigest is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.